The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis

被引:88
作者
Cunnane, G [1 ]
Madigan, A [1 ]
Murphy, E [1 ]
FitzGerald, O [1 ]
Bresnihan, B [1 ]
机构
[1] St Vincents Univ Hosp, Dept Rheumatol, Dublin 4, Ireland
关键词
rheumatoid arthritis; inflammation; synovial membrane; interleukin-1 receptor antagonist; macrophages;
D O I
10.1093/rheumatology/40.1.62
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the: effects of treatment with interleukin-1 receptor antagonist (IL-1Ra) on synovial tissue in rheumatoid arthritis (RA). Methods. Twelve patients with RA entering a randomized clinical trial of human recombinant IL-1Ra underwent synovial biopsies before and after treatment. Cellular infiltration and adhesion molecule expression were evaluated after immunohistochemical staining. Results. There was a notable reduction in intimal layer macrophages and subintimal macrophages and lymphocytes after treatment with IL-1Ra at 150 mg/day (n = 3. Increased cellular infiltration was observed in all patients receiving placebo (n = 3); variable changes were observed after IL-1Ra 30 mg/day (n = 6). In a limited study of adhesion molecule expression, down-regulation of E-selectin and vascular cell adhesion molecule-1 was observed after treatment with IL-1Ra 150 mg:day, but not after IL-1Ra 30 mg/day or placebo. The apparent arrest of progressive joint damage seen in four patients after treatment with IL-1Ra was associated with reduced intimal layer macrophage accumulation in all patients. Conclusion. Treatment of RA with IL-1Ra resulted in reduced mononuclear cell infiltration of synovial membrane, which may represent the in vivo inhibition of biologically relevant IL-1 beta -mediated pathogenic effects.
引用
收藏
页码:62 / 69
页数:8
相关论文
共 34 条
  • [1] INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (02): : 151 - 160
  • [2] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [3] Bresnihan B, 1998, BRIT J RHEUMATOL, V37, P636
  • [4] Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO
  • [5] 2-2
  • [6] Burger D, 1998, ARTHRITIS RHEUM, V41, P1748, DOI 10.1002/1529-0131(199810)41:10<1748::AID-ART7>3.3.CO
  • [7] 2-V
  • [8] Mononuclear phagocytes and rheumatoid synovitis - Mastermind or workhorse in arthritis?
    Burmester, GR
    Stuhlmuller, B
    Keyszer, G
    Kinne, RW
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (01): : 5 - 18
  • [9] DINARELLO CA, 1993, NEW ENGL J MED, V328, P106
  • [10] ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362